This is particularly important in the era of new, effective medical therapies that reduce adiposity and implies that adiposity might represent a novel therapeutic target for patients with prostate cancer.44,45 Finally, based on the results of our study, serum leptin levels could also be used as a marker for patient risk stratification and personalization of prostate cancer treatment by guiding preventive cardiovascular therapies such as statins. This evidence concerns the gene LEP and prostate carcinoma.